MediciNova Announces the Initiation of the Phase III Clinical Program for MN-001, a Novel Oral Treatment for Bronchial Asthma
16th Nov 2006, 19:41 GMT
MediciNova a biopharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange, announced the initiation of its Phase III clinical program to determine the safety and efficacy of its novel oral treatment for bronchial asthma in asthma patients.
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress